Inhibition Of Paclitaxel/NLS-KALA-SA Nanoparticles On A549 Cell Lines In Vitro

Objective: Investigation paclitaxel/ NLS-KALA-SA localization of nanoparticles on lung adenocarcinoma A549 cells in vitro effect and mechanism. Methods: Use MTT assay to test 24 h, 48 h and 72 h,s cell proliferation about different concentrations NKS(20,40,80,100μg/L). Use MTT assay to test 24 h, 48 h and 72 h,s cell proliferation about different concentrations NKSP(20,40,80,100μg/L) and paclitaxel monotherapy(20,40,80,100μg/L). Subsequent experiments were divided into four groups, namely, without any drug treatment group(A) was added polypeptide 80μg/L of self-assembled nanoparticles(NKS) broth(B) group, plus and 80μg/L paclitaxel monotherapy group(C), solution containing 80μg/L NKSP(D) group.Those four group’s Cell apoptotic rate were analyzed by cytometry atter 48 h and 72 h. The four group’s protein expressions of bax and caspase-3 were studied by Western Blot. Results: NKS couldn,t inhibit the proliferation of A549 cell. Both paclitaxel monotherapy and NKSP could inhibit the proliferation of A549 cell. When paclitaxel monotherapy groups at 48 h and 72 h with increasing concentrations inhibition rate and also showed an increasing trend( P <0.05). NKSP monotherapy with increasing concentrations of each group at 72 h inhibition rate showed an increasing trend( P <0.05). After treated for 48 hours, the apoptotic rate of C group were higher than that of D group(P<0.05). But 72 hours later the apoptotic rate of C group were less than that of D group(P<0.05). Western blot showed that C group and the D group increased protein express of bax and caspase-3 in a dosedependant manner. Conclusion: Paclitaxel/ NLS-KALA-SA nanoparticles were round or oval shape, particle size distribution.Paclitaxel/ NLS-KALA-SA nanoparticles having Delivery System. Paclitaxel/ NLS-KALA-SA nuclear localization of nanoparticles compared with paclitaxel monotherapy, can reduce cytotoxicity, more effectively inhibit the proliferation of A549 lung cancer cells.